DR TOMAS KALINCIK

DR TOMAS KALINCIK

Positions

  • Biostatistics (disease outcome models, prediction markers)
  • Epidemiology (risk factors and prediction markers, natural disease course, treatment outcomes)
  • Muptiple sclerosis (genetics, prediction, biomarkers, associated diseases, treatment)

Overview

Affiliation

Member of

  • Medical Board of Australia. limited registration 2012 -
  • Federation of European Neurosciences. member 2008 -
  • Czech Medical Chamber. registered 2009 - 2011
  • Czech Neurological Society. member 2009 - 2011
  • Movement Disorder Society. member 2009 - 2010
  • Australian Neuroscience Society. member 2007 - 2008
  • Slovak Medical Chamber. registered 2005 - 2006

Publications

Selected publications

Research

Investigator on

Awards

Education and training

  • N/A, Charles University in Prague 2015
  • PGCertBiostat, University of Melbourne 2014
  • PhD, University of New South Wales 2009
  • MD, Charles University in Prague 2005

Awards and honors

  • NHMRC Fellowship, 2013
  • Not in List, 2012
  • Postgraduate Research Student Support Scheme, University of New South Wales, 2006
  • School of Medical Sciences Research Scholarship, University of New South Wales, 2006
  • Postgraduate Research Scholarship, University of New South Wales, 2006

Linkages

Supervision

Available for supervision

  • Y

Supervision Statement

  • Position Description
    Title: MSBase at Melbourne Brain Centre Postgraduate Research Scholarship
    Full-time PhD position commencing in 2016
    Primary supervisor: Dr Tomas Kalincik
    Co-supervisor: Prof Helmut Butzkueven
    Contact: tomas.kalincik@unimelb.edu.au

    Research Scope
    Theme
    Modelling disease outcomes in multiple sclerosis

    Synopsis
    Multiple sclerosis is the most common cause of neurological disability among young adults, with the peak of onset in 3-4th decades of life. Almost half of the patients with multiple sclerosis ultimately develop severe limitation of activities of daily living and independence, and less than half of the patients maintain employment. Immunomodulatory disease modifying therapies represent the standard of disease management in patients with relapsing multiple sclerosis. However management of progressive multiple sclerosis, prediction of disease outcomes and individually-tailored therapy still remain to be resolved.
    This postgraduate research scholarship will utilise a global observational cohort study and statistical modelling, including analysis of longitudinal data, propensity score-based methods and individual predictive analysis, to address the questions of (i) treatment and outcomes of progressive multiple sclerosis, (ii) early predictive markers of treatment response, and (iii) the outcomes of various management decisions and treatment pathways.

    Impact

    The research completed in the course of the candidature will inform clinical practice of multiple sclerosis management globally. It will further our understanding of predictors of treatment response and will enable individualised multiple sclerosis therapy. The student will develop knowledge observational clinical research, multivariable modelling, analysis of longitudinal data, neuroepidemiology and multiple sclerosis &ndas